嵌合抗原受体T细胞治疗复发难治性多发性骨髓瘤的最新研究进展  

New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma——Review

作　　者：张芳荣 李昕[1] 刘竞[1] ZHANG Fang-Rong;LI Xin;LIU Jing(Department of Hematology,Xiangya Third Hospital,Central South University,Changsha 410013,Hunan Province,China)

机构地区：[1]中南大学湘雅三医院血液科

出　　处：《中国实验血液学杂志》2019年第4期1316-1320,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金(81670203)

摘　　要：嵌合抗原受体T细胞(chimeric antigen receptor-T cells,CAR-T)是用基因工程的方法进行人工改造的T细胞。CAR-T细胞可以表达肿瘤抗原特异性受体,该受体能特异性地识别并结合恶性肿瘤细胞,CAR-T细胞被激活时,可利用细胞毒性作用杀伤肿瘤细胞,该方法已在临床上成功地运用于治疗多种血液系统恶性肿瘤,如ALL、CLL、NHL、MM等。CAR-T细胞常被用于治疗复发难治性多发性骨髓瘤(RRMM),已有许多研究机构报道了其在临床试验中取得的成果,该方法提高了MM患者的治疗效果并延长生存时间。本文从多种CAR-T的疗效、不良反应、机遇与挑战等方面进行综述。Chimeric antigen receptor-T cell( CAR-T) is a kind of genetically engineered T cells that can express tumor antigen-specific receptors on its surface,and the modified T cells can be used for cancer therapy through targeting malignant tumor cells with its specific receptor and killing tumor cells with its cytotoxicity.CAR-T has been successfully applied to treat various hematological malignancies,such as ALL,CLL,NHL and MM.It is a feasible treatment for relapsed and refractory multiple myeloma ( RRMM).The achievements of CAR-T in clinical trials have been widely reported,which is expected to be a therapy to prolong patients survival.In this review,the clinical application of CART in the treatment of RRMM from the following aspects:different types of CAR-T and its curative efficacy,adverse effects,opportunities and challenges are summarized beriefly.

关 键 词：嵌合抗原受体T细胞 复发难治性多发性骨髓瘤 细胞免疫治疗 

分 类 号：R733.3[医药卫生—肿瘤]